oncology

Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
BioSpace
Pfizer
Concerto HealthAI
oncology
real world data
real world evidence
Flag link:
Bristol-Myers Squibb and Concerto HealthAI Sign Cancer Real World Data Agreement
Bristol-Myers Squibb and Concerto HealthAI Sign Cancer Real World Data Agreement
BioSpace
Bristol-Myers Squibb
Concerto HealthAI
oncology
real world data
real world evidence
artificial intelligence
Flag link:
Early Stage Oncology Biotech Files for $100 Million IPO
Early Stage Oncology Biotech Files for $100 Million IPO
CP Wire
Turning Point Therapeutics
IPOs
oncology
Flag link:
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Fierce Biotech
Celgene
Exscientia
artificial intelligence
oncology
autoimmune disease
drug discovery
Flag link:
Life Science Investment Grew 50% 2018 over 2017 -- New JD Supra Life Sciences Report
Life Science Investment Grew 50% 2018 over 2017 -- New JD Supra Life Sciences Report
CP Wire
JD Supra
investment
devices
biotech
IPOs
oncology
Flag link:
Life Science Investment Grew 50% 2018 Over 2017 -- New JD Supra Life Sciences Report
JD Supra
investment
devices
biotech
IPOs
oncology
Flag link:
FDA looks to broaden cancer trial eligibility
FDA looks to broaden cancer trial eligibility
BioCentury
FDA
cancer
clinical trials
oncology
Flag link:
AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres
AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres
Endpoints
AstraZeneca
oncology
microbiome
Seres Therapeutics
Flag link:
Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut
Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut
Endpoints
Oncternal
GTx
NASDAQ
oncology
Flag link:
Gilead oncology chief departing to head up Glenmark spin-out
Gilead oncology chief departing to head up Glenmark spin-out
Biopharma Dive
oncology
Alessandro Riva
Gilead Sciences
Glenmark
Flag link:
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
M&A
oncology
neurology
Rare Diseases
Pfizer
Merck
JNJ
Biogen
Biomarin
Flag link:
2 Pharma Stocks in the Middle of an Oncology Sales Explosion
2 Pharma Stocks in the Middle of an Oncology Sales Explosion
Motley Fool
oncology
Roche
AbbVie
AstraZeneca
Flag link:
Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today
Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today
Endpoints
Sanofi
oncology
Flag link:
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Pharmaforum
CAR-T
CAR-T Congress
oncology
Novartis
Kymriah
Europe
Flag link:
Pfizer’s Cancer Portfolio Expected to Rake in $8.3 Billion in 2019
Pfizer’s Cancer Portfolio Expected to Rake in $8.3 Billion in 2019
BioSpace
Pfizer
oncology
cancer
Flag link:
A two-fisted punch against cancer metastasis
A two-fisted punch against cancer metastasis
Fierce Biotech
cancer
MMP inhibitors
Duke University
oncology
Flag link:
GSK closes acquisition of Tesaro for $5.1bn
GSK closes acquisition of Tesaro for $5.1bn
Pharmaceutical Business Review
GSK
Tesaro
M&A
oncology
Flag link:
ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors
ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors
Pharmaceutical Business Review
ADC Therapeutics
oncology
ADCT-601
solid tumors
clinical trials
Flag link:
AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure
AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure
Fierce Pharma
AstraZeneca
reorganization
oncology
restructuring
Flag link:
Pfizer, Merck shares smoking hot in 2018 despite doldrums for overall biopharma sector
Pfizer, Merck shares smoking hot in 2018 despite doldrums for overall biopharma sector
Fierce Pharma
oncology
Merck
Pfizer
Flag link:

Pages